- New GLP-1 “microdose” program: Telehealth company Hims & Hers (NYSE: HIMS) announced on Oct 29, 2025 that it will begin offering clinician-supervised compounded GLP-1 microdosing plans to address metabolic health beyond BMInews.hims.comtipranks.com. The plans use ultra-low doses of semaglutide (same as Ozempic/Wegovy) tailored to patients with risk factors like sleep apnea or high blood pressurenews.hims.com.
- Program details: Hims’ doctors tout emerging research that GLP-1 drugs lower inflammation markers independent of weight loss, and see microdosing as a way to “minimize side effects” and improve adherencenews.hims.comnews.hims.com. The six-month microdose package will cost $1,200 upfronttipranks.com, matching Hims’ existing compounded GLP-1 offerings. (By comparison, Novo Nordisk’s Wegovy is over $900/month retail.) All dispensed drugs require prescription and come from licensed pharmacies, though Hims notes these compounds “are not reviewed for safety or efficacy by the FDA”news.hims.com.
- Expert views – cautious balance: Hims’ medical lead stresses microdosing is “early-stage” but promisingnews.hims.com. However, independent experts warn evidence is lacking. Endocrinologists emphasize that microdosing is not FDA-approved and safety data are scarce. For example, one obesity specialist notes that giving smaller GLP-1 doses can still cause side effects (nausea, gut issues, etc.) and that compounded formulations carry unknown risksmedicalnewstoday.com. A Hackensack Meridian endocrinologist bluntly states safety “is unknown” without formal studiesmedicalnewstoday.com. Others echo that microdosing might work for maintenance or minor weight goals, but “it may not be as effective” as full doses for major weight lossmedicalnewstoday.com. Nutrition experts caution patients to vet sources carefully, since compounded semaglutide isn’t FDA-testedmedicalnewstoday.commedicalnewstoday.com.
- Regulatory context: In early 2025 the FDA ended the Ozempic/Wegovy shortage and told compounders (like Hims) to stop copying GLP-1 injectablesbusinessinsider.com. Hims had been a big seller of such “copycat” weight-loss shots ($199/month vs brand $900)businessinsider.com, but the company said it would phase those out after FDA’s updatebusinessinsider.com. Instead, Hims pivoted to a new partnership with Novo Nordisk to bundle brand Wegovy via its platform (at $599/month total)businesswire.com. Now, Hims’ microdosing uses compounded semaglutide at lower doses – a legal gray zone that regulators are monitoring. Notably, Hims’ press release explicitly warns: “Compounded drug products are not approved or evaluated for safety… by the FDA”news.hims.com. This reflects broader warnings (FDA and medical groups have flagged counterfeit/compounded GLP-1 risks)foxnews.comfoxnews.com.
- Stock reaction & market: HIMS stock (~$45 as of early Nov. 2025) is volatile but up about +87% year-to-date. A late-Oct bump (+2–3%) followed news that JPMorgan bought up ~17.8M shares (~8.1% of HIMS). However, the stock had slipped ~20% in October amid CEO share sales (Andrew Dudum sold ~$11M, per SEC filings) and regulatory uncertainty. Wall Street consensus is cautious: analysts rate HIMS a Hold (8 holds, 2 buys, 2 sells) with an average price target ~$49.75 (≈9% above current). After Q2’s growth slowdown, Q3 ’25 estimates foresee ~$580 million revenue (+40% YoY) and ~$0.09 EPS. The options market is braced for a ~15% stock swing around the Nov 3 earnings release.
- Broader strategy: Beyond weight loss, Hims has been rapidly expanding its telehealth offerings. In late 2025 it launched a women’s menopause/perimenopause specialty (aiming for $1 billion Hers revenue by 2026)businesswire.com, and a men’s health category with new branded oral testosterone (KYZATREX®) and compounded hormone therapiesbusinesswire.combusinesswire.com. CEO Dudum emphasizes “access and affordability” across these initiatives. Hims also continues a weight-loss collaboration with Novo Nordisk (Wegovy bundles)businesswire.com and claims 2.4M subscribers globally.
Analyst outlook & forecast: Long-term, analysts model robust growth. For example, one financial model projects ~18% revenue CAGR: ~$3.3 billion in sales by 2028 and ~$261 million net incomesimplywall.st. Another estimate sees revenue rising from ~$2.35 B in 2025 to ~$3.34 B by 2027tipranks.com, and free cash flow turning positive in 2025simplywall.st. These forecasts assume continued momentum in weight-loss/metabolic services plus gains in new verticals. Yet many investors note the high valuation (HIMS trades near ~$45 with market cap in the billions) and regulatory/legal risks. Community “fair value” estimates vary widely (some as low as $41) due to uncertaintysimplywall.st. Key analysts (TD Cowen, KeyBanc) maintain Holds in light of decelerating growth and competition, though they acknowledge solid subscription volumes and expanding offeringstipranks.com.
Bottom line: Hims & Hers is front-running the latest GLP-1 craze by marketing a “microdose” treatment, betting it can carve out a niche in preventive metabolic carenews.hims.comtipranks.com. Medical experts see both potential (earlier intervention, fewer side effects) and pitfalls (lack of data, safety unknown)medicalnewstoday.comnews.hims.com. Investors will be watching its Nov. 3 earnings for any sign that these new services boost subscriber growth or cross-selling, against a backdrop of intense industry competition (Lilly/Novo, other telehealth, insurance pressures). With consensus targets only modestly above current levelstipranks.com, the stock’s future hinges on execution across weight loss, men’s and women’s health, and how regulators treat compounded GLP-1 therapies. In Dr. Primack’s words: “microdosing is an important step for metabolic health,” but analysts and FDA observers alike urge caution until real-world outcomes emergenews.hims.commedicalnewstoday.com.
Sources: Hims & Hers press release; TipRanks analysis; SimplyWallSt data; Financial Press (Economic Times, Business Insider); Fox News health reports; Medical News Today; Sherwood News (investor news).
